Textbook: Aschengrau A. and Seage III GR. Essentials of Epidemiology in Public Health. Jones and Bartlett, Publishers. Boston, MA 2003.

Sexual Transmission

Seage GR, Mayer KM, Horsburgh CR, Holmberg SD, Moon MW, Lamb GA. The Relationship Between Nitrite Inhalants, Unprotected Receptive Anal Intercourse and the Risk of HIV Infection. Am J Epidemiol. 1992;135:1 11. Full Text

Seage GR, Mayer KM, Horsburgh CR, Cai B, Lamb GA. Corroboration of Sexual Histories Among Male Homosexual Couples. Am J Epidemiol. 1992;135:79 84. Full Text

Seage GR, Mayer KH, Horsburg CR Jr. Risk of HIV infection from unprotected receptive anal intercourse increases with decline in immunologic status of HIV infected partners. Am J Epidemiol. 1993;137:899 908. Full Text

Seage GR, Mayer, KM, Wold C, Lenderking WR, Goldstein R, Cai B, Gross M, Heeren T, Hingson R. The social context of drinking, drug use and HIV risk in the Boston Young Men’s Study. J Acqui Immune Defic Synr Human Retrovirol. 1998;17:368-375.

Hammett TM, Mason TH, Joanis CL, Foster SE, Harmon P, Robles RR, Finlinson A, Feudo R, Vining-Bethea S, Jeter G, Mayer KH, Doherty-Iddings P and Seage III GR. Acceptability of formulations and application methods for Vaginal Microbicides Among Drug-Involved Women: Results of Product Trials in Three Cities. Sex Transm Dis. 2000;27:119-126. Abstract

Metzger DS, Koblin B, Turner C, Navaline H, Holte S, Gross M, Sheon A and Seage III GR. A Randomized Controlled Trial of Audio-Assisted Computer Self-Interviewing: Impact, Feasibility, and Acceptability. Am J Epidemiol. 2000;152:99-106. Full text

Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage III GR. Both homozygous and heterozygous CCR-5 delta 32 genotypes are associated with resistance to HIV infection in a high risk cohort. J Acqui Immune Defic Synr Human Retrovirol. 2001;27:472-481. Full text

Seage III GR, Holte S, Gross M, Koblin B, Marmor M, Mayer KH, Lenderking W. A case crossover study of partner and situational factors for unprotected sex. J Acqui Immune Defic Synr Human Retrovirol. 2002;31:432-439. Full text

HIV Vaccine Trial Design

Koblin BA, Heagerty P. Sheon AR, Metzger DS, Buchbinder SP, Celum C, Douglas JM, Gross M, Marmor M, Mayer K, Seage III GR. Readiness of high-risk populations in the HIV Network for Prevention Trials (HIVNET) to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793. Full text

Seage III GR, Holte S, Metzger D, Koblin BA, Gross M, Celum C, Marmor M, Woody G, Mayer KH, Stevens C, Judson FN, McKirnan D, Sheon A, Self S, Buchbinder SP. The HIVNET Vaccine Preparedness Study (VPS): Are United States Populations Appropriate for HIV Vaccine Trials? Am J Epidemiol. 2001;153:619-627. Full text

Coletti AS, Heagerty P, Shoen A, Gross M, Koblin BA, Metzger DS and Seage III GR. Randomized, controlled evaluation of a prototype informed consent process for domestic HIV vaccine trials. J Acqui Immune Defic Synr Human Retrovirol. 2003:32:161-169. Full text


Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson G, Seage III GR, Song LY, Dankner WM, Oleske J, For the Pediatric AIDS Clinical Trials Group Protocol 219 Team. The Impact of Protease Inhibitor Combination Therapy on Mortality Among Children and Youth Infected With HIV-1. N Engl J Med. 2001;345:1522-8.

Seage III GR, Losina E, Goldie SJ, Paltiel AD, Freedberg KA. The role of preventable opportunistic infections, HIV RNA viral load and CD4+ cell counts on chronic mortality. J Acqui Immune Defic Synr Human Retrovirol. 2002;30:421-428. Full text

Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Seage III GR. Malignancy in perinatally HIV infected children in the United States. Pediatr Infect Dis J. 2005 Mar;24(3):237-242. Full text

Brogly S, Williams P, Seage III GR, Oleske J, McIntosh K, for the PACTG 219C Cohort Antiretroviral treatment use in pediatric HIV in the United States: from clinical trials to clinical practice. JAMA. 2005;293:18:2213-2220.

Sharghi N, Bosch RJ, Mayer KH, Essex M, Seage III GR. Predictive value of clinical factors associated with HIV-1 seroconversion among high-risk participants of a vaccine preparedness study. J Acqui Immune Defic Synr Human Retrovirol. 2005;40:472-478. Full text

Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MM, Nachman SA, Seage III GR. Incidence of Opportunistic and Other Infections in HIV-Infected Children in the HAART-Era. JAMA. 2006;296:292-300. Full text

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage III GR, for the Pediatric AIDS Clinical Trials Group Protocol 219C Team. Risk Factors for Opportunistic Illnesses in Children Infected with Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy. Arch Pediatr Adolesc Med. 2006;160:778-87. Full text

Seage III GR, Buchacz K, Weinberg GA, Patel K, McIntosh K, Dankner WM. The Pediatric AIDS Survival Score (PASS): A Multidimensional AIDS Severity Adjustment for Pediatric HIV Infection. In Press, J Acqui Immune Defic Synr Human Retrovirol. Abstract

Patel K, Weinberg GA, Buchacz K, McIntosh K, Dankner WM, and Seage III GR, for the Pediatric AIDS Clinical Trials Group 219 Study Team. Simple PASS (Pediatric AIDS Severity Score): A pediatric severity score for resource-poor settings. In press, J Acqui Immune Defic Synr Human Retrovirol. Abstract